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Introduction: New devices for endovascular treatment of thoracic aortic diseases were recently approved for clinical use by
European authorities, obtaining the Conformite´ Europe´enne (CE) mark. In all patients who underwent endovascular
treatment of a thoracic aortic disease in 2002, we used a new CE-marked device, the Endofit stent graft. The device is
constituted of nitinol stents and polytetrafluoroethylene fabric, and has a simple design and delivery system.
Methods: During 2002, 11 patients (mean age, 75 years; range, 66-85 years) underwent treatment of atherosclerotic
aneurysm (n 9), chronic type B dissection (n 1), and intramural hematoma (n 1). Disease involved the descending
thoracic aorta in 7 patients and the distal aortic arch in 4 patients.
Results: In all cases the Endofit stent grafts were successfully deployed in the intended position. No postoperative
paraplegia or paraparesis was recorded. There were two in-hospital deaths: 1 patient died in the operating room
(postmortem examination showed a kinked graft); and the other patient died in the intensive care unit on postoperative
day 30, after an intraoperative stroke. One surgical conversion was performed 2 weeks after the procedure, because of
total collapse of the graft due to rupture of three stents. Other graft-related complications included type I endoleak (n
2), type II endoleak (n  1), and incomplete opening of the device (n  1).
Conclusion: Endovascular treatment of thoracic disease with the Endofit graft in this small heterogeneous group of
patients resulted in several complications, which may arise from both the delivery system and the graft itself. At present,
other commercially available endografts may be safer for endovascular treatment of thoracic aortic diseases. (J Vasc Surg
2004;39:124-30.)
The feasibility and safety of stent-graft therapy for
thoracic aortic aneurysms was initially investigated by Dake
et al1 in 1992, using homemade devices that combined
polyester grafts and modified Gianturco Z-stents. This
therapeutic concept proved successful, not only in treat-
ment of aneurysm, but also other aortic diseases, such as
dissection,2 intramural hematoma (IMH),3 penetrating ul-
cer,4,5 traumatic injury,6-8 and anastomotic aneurysm.9
Both ready-made and custom-made grafts soon became
commercially available.
The most popular commercially manufactured thoracic
stent grafts were the Talent (AVE/Medtronic, Santa Rosa,
Calif) and Excluder (W. L. Gore & Associates, Flagstaff,
Ariz) stent grafts. However, structural problems with the
Excluder graft were detected during follow-up, and in
November 2001 the manufacturer voluntarily withdrew
this product from the market.10
Other stent grafts have become commercially available
in recent years, such as the Zenith (William Cook Europe,
Bjaeverskov, Denmark) and Endofit (Endomed, Phoenix,
Ariz) grafts, which obtained Conformite´ Europe´enne (CE)
marking in June 2001.10 To our knowledge, phase 1 of the
US Food and Drug Administration (FDA) approval process
for the Endofit graft is currently under way at several US
centers. The simple design and delivery system, reduced
cost, and favorable preliminary results presented to us by
the manufacturer induced us to implant the Endofit graft in
our patients in 2002. The purpose of this study was to
evaluate the clinical results of endovascular treatment of
diseases of the thoracic aorta with this new commercially
available and CE-marked stent graft.
MATERIAL AND METHODS
During 2002 at our institution, 11 patients underwent
treatment of thoracic aortic disease with the Endofit graft.
Demographic data are presented in the Table. All patients
were men, with mean age 75 years (range, 66-85 years).
Disease involved the distal arch in 4 patients and the
descending aorta in 7 patients. One patient had chronic
dissection, one patient had an intramural hematoma, and
the remaining nine patients had atherosclerotic aneurysms
(mean diameter, 6.8 cm).
This series comprises all patients with thoracic aortic
disease treated with an endovascular approach in 2002 at
our institution. Over the same period, 16 patients under-
went open surgical treatment of disease involving the tho-
racic aorta, and 3 patients were observed with medical
therapy alone, because we believed they were too sick to
undergo either open surgical or endovascular procedures.
In three procedures the graft was implanted after ad-
ministration of subarachnoid anesthesia, and in eight pro-
cedures the patient was under general anesthesia. The
preferred access site was the right common femoral artery,
possible in nine patients. In one of the remaining patients,
we used right common iliac artery access through a retro-
peritoneal approach, and in the other patient we used the
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left branch of a previous aortobiiliac bypass graft, also
through a retroperitoneal approach. Control angiographs
were obtained with a 6-8F introducer sheath inserted
through the contralateral femoral artery or the left brachial
artery in 2 patients.
All procedures were performed in the operating room,
under fluoroscopic control with a mobile digital C-arm
image intensifier (OEC Medical Systems Inc, Salt Lake
City, Utah). A bolus of heparin (70 IU/kg) was adminis-
tered at deployment of the graft, and controlled systemic
hypotension was induced pharmacologically by the anes-
thesiologist with a bolus of fast-acting venous or arterial
vasodilator, such as nitrate or urapidil. Nitroprusside or
adenosine-induced asystole were never used.
The Endofit device is composed of nitinol stents com-
bined with expandable polytetrafluoroethylene (ePTFE)
fabric, with an uncovered proximal stent, and comes loaded
in a cartridge. Each stent is separated from the others, and
only the top “free-flow” stent is linked to the first covered
stent. All stents except the proximal free-flow stent are
sandwiched between two layers of ePTFE in a thermal
process of encapsulation that avoids the need for sutures.
Therefore, there is no interface of metallic stent with either
the blood or the aortic wall. No longitudinal structures for
columnar support are present.
A 24F introducer sheath with tapered conic dilator is
inserted over a guide wire up to the site intended for
deployment of the graft or above it. The dilator is then
withdrawn, and the stent graft is inserted into the sheath
and advanced all the way up with a pusher. At this point,
however, the sheath can no longer be safely advanced
forward, because its tip is no longer tapered; it can only
be withdrawn, if necessary. The stent graft is simply
deployed by holding still on the pusher as the sheath is
Demographic data
Patients Sex Age (y) Lesion
Graft size
(mm) In-hospital outcome
No. 1 Male 71 Distal arch aneurysm 40  140 Graft migration, intraoperative death
No. 2 Male 77 Distal arch aneurysm 36  140 Type I endoleak; discharged
No. 3 Male 69 DTAA 38  220 Asymptomatic incomplete graft release;
discharged
No. 4 Male 85 DTAA 40  140 Discharged
No. 5 Male 75 Dissected DTAA 30  140 Discharged
No. 6 Male 81 Distal arch aneurysm 36  140 Discharged
No. 7 Male 79 DTAA 36  140 Type II endoleak; discharged
No. 8 Male 74 IMH of descending
aorta
32  140 Stroke, perioperative death
No. 9 Male 66 DTAA 36  140 Discharged
No. 10 Male 77 DTAA 34  140 Type I endoleak; discharged
No. 11 Male 71 Distal arch aneurysm 36  180 Discharged; subsequent open surgery because
of collapse of graft, due to fracture of three
stents; discharged; alive and well
DTAA, Distal thoracic aortic aneurysm; IMH, intramural hematoma.
Fig 1. Case 1. Photographs obtained at postmortem examination. A, After removal of thrombus, new thrombosis
formed around the stent graft. Note kinking of the graft within the aneurysmal sac. B, Endograft after complete removal
of old and fresh thrombi.
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withdrawn. Control aortograms are obtained. Visibility
of the nitinol stents is good, and the graft usually does
not require balloon expansion. Postoperative computed
tomography (CT) scans were obtained in all patients but
one, before discharge from the hospital. Follow-up CT
scans were obtained every 6 months for the first year;
additional aortograms were also obtained in patients
with endoleak.
Fig 2. Case 11. A, Early postoperative x-ray film shows correct endograft deployment. B, X-ray film obtained 2 weeks
later shows total collapse of the graft. C, CT scan obtained 2 weeks after graft implantation.
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RESULTS
In all 11 patients, the Endofit stent grafts were success-
fully deployed in the intended position.
There were no complications related to the access site
or to anesthesia, and no postoperative paraplegia or para-
paresis. Two in-hospital deaths (18%) occurred: one patient
died in the operating room; the other patient died in the
intensive care unit on postoperative day 30, due to intra-
operative stroke.
The patient who died in the operating room was ad-
mitted for treatment of a distal arch saccular aneurysm with
maximum diameter 7.5 cm. The history included hyperten-
sion, myocardial infarction, coronary artery bypass graft
implanted 10 years previous but no longer patent, abdom-
inal aortic aneurysm repair, pacemaker implantation, and
obstructive pulmonary disease. An aortogram revealed a
proximal neck 36 mm in diameter and 30 mm long be-
tween the left common carotid artery and the left subcla-
vian artery. The stent graft was delivered at the intended
site without complications, and a completion aortogram
showed complete exclusion of the aneurysm and no en-
doleak. No balloon expansion was performed. One hour
after completion of the procedure, the patient had severe
hypotension and cardiac arrest. Cardiopulmonary resusci-
tation was attempted for 45 minutes, and defibrillation was
Fig 3. Case 11. Surgical removal of collapsed endograft during
open surgical repair with partial left atriofemoral bypass with
centrifugal pump.
Fig 4. Case 11. Direct examination of the device shows rupture of
three stents.
Fig 5. Case 2. Fluoroscopic examination shows proximal covered
stent (arrows) adherent to aortic wall (dashed line) during diastole
(A) and diverging from aortic wall during systole (B). Angiogram
shows a type I endoleak during systole (C).
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performed several times without result. Postmortem exam-
ination revealed severe pulmonary congestion, left ventric-
ular hypertrophy and dilatation, and, to our surprise, that
the stent graft was completely kinked within the aneurysm
(Fig 1). The proximal end was between the left common
carotid artery and the left subclavian artery.
The other patient who died underwent treatment of an
intramural hematoma, and intraoperative stroke occurred.
CT scans showed that it was caused by a cerebellar ischemic
infarction with mass effect. Despite emergent external ven-
tricular drainage, severe hydrocephalus developed. The pa-
tient was admitted to the intensive care unit, but never
recovered. He was comatose and required prolonged respi-
ratory assistance and tracheotomy, and died on postopera-
tive day 30.
Postmortem examination showed that the stent graft
was intact and well-expanded. The aortic arch, especially in
the area of the origin of the supra-aortic trunks, was ather-
omatous. Emboli may well have originated from this area
during stent-graft positioning and deployment.
In another patient, with a distal arch aneurysm, the
graft was deployed successfully (Fig 2, A). However, 2
weeks after the procedure a routine chest x-ray study (Fig 2,
B) and CT scan (Fig 2, C) showed total collapse of the
graft, as a result of fracture of three stents that perforated
the e-PTFE. The patient had no symptoms. Femoral pulses
were decreased but still palpable, because flow was present
between the collapsed graft and the aortic wall. Open
surgery was performed, with partial left atriofemoral bypass
with a centrifugal pump. The aorta was clamped proximally
between the left common carotid artery and the left sub-
clavian artery. The stent graft was easily removed (Fig 3),
and graft replacement was performed with routine tech-
nique. Direct examination of the device confirmed rupture
of the three stents (Fig 4). The postoperative course was
uneventful, and the patient was discharged on postopera-
tive day 6.
In the 2 patients with type I endoleak, it was deter-
mined that leakage originated from the proximal neck. At
fluoroscopy (Fig 5, A-C), the first covered stent was ob-
served to move in and out from the aortic wall during the
cardiac cycle, and it was not fully adherent to the proximal
neck during systole. Further treatment will be needed in
these patients.
Fig 6, obtained at postmortem examination in the
patient who died perioperatively, clearly demonstrates that
at this level the PTFE fabric is not adherent to the aortic
wall and that during systole the force of the blood may
produce movement of the stent, as in the patient in Fig 5.
In this patient, however, the indication for the procedure
was intramural hematoma, and therefore no endoleak was
present, which was probably not relevant to the final out-
come.
The single type II endoleak was small, and probably
due to intercostal branches. One of the middle stents did
not open completely (Fig 7); however, this did not seem to
be clinically relevant, because the proximal end distal stents
sealed the aneurysm satisfactorily. We were not able to
observe a stent rupture in this case. We are closely observing
all patients with endoleak.
DISCUSSION
Open surgical repair of distal arch and descending
thoracic aortic diseases with graft placement is a reliable and
durable treatment for aneurysms and other serious condi-
tions. However, morbidity and mortality may be as high as
25% to 28%.11 Patient age and preoperative comorbid
conditions, such as cardiac, respiratory, renal, and neuro-
logic disease, may greatly increase risk. Because it is less
invasive, endovascular treatment is an attractive alternative,
especially in patients at high risk.12 The technique may be
performed with the patient under locoregional anesthe-
sia13; we generally use subarachnoid anesthesia. The pro-
cedure is associated with much less hemodynamic alter-
ation, blood loss, and ischemia to the splanchnic, renal, and
spinal regions.14 It also seems to limit immune cell activa-
tion and the systemic inflammatory response syndrome
associated with open surgical repair of aneurysm.15
On the other hand, little is known about long-term
safety and durability of the stent grafts that we are implant-
ing. Therefore, in younger patients with good surgical risk,
open surgery may still be the best choice.
The Excluder device, for example, which produced
good short-term results,16 is no longer available, because
the manufacturer voluntarily withdrew it from the market
after mechanical failure was discovered in several patients at
follow-up.10 Patients with these devices are now scruti-
nized closely to determine the clinical relevance of these
failures. As of March 10, 2003, spinal fracture was found in
26 devices worldwide, of the more than 2500 devices
implanted in more than 2000 patients. Thus far, no fracture
has resulted in any adverse clinical sequelae. The fracture
rate in the United States is approximately 10% (19 of 207
patients). To date, only eight fractures have been found in
patients outside of the United States (M. Nilson, W. L.
Fig 6. Case 8. At postmortem examination the proximal end of
the expandable polytetrafluoroethylene fabric of the stent graft was
not adherent to the aortic wall.
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Gore & Associates, Flagstaff, Ariz, personal communica-
tion, March 2003).
Our policy has been to use endovascular treatment for
diseases of the distal arch and descending thoracic aorta in
patients who are poor candidates for surgery. In 2002, 16
patients underwent open treatment and 11 patients re-
ceived a stent graft. In the same period only three patients
at our institution were believed to be unfit for either
procedure and were observed with medical therapy only.
Until definitive results from randomized surgical trials are
available, we believe this prudent attitude is acceptable.
All patients with endografts must be followed up care-
fully over time, because previous experience has demon-
strated the possibility of aortic rupture despite absence of
endoleak on postoperative CT scans.17
The Endofit stent graft is a CE-marked product. The
CE mark (abbreviation of a French phrase, Conformite´
Europe´enne) is affixed by the manufacturer to certain prod-
ucts for access to the European market (consisting of 18
countries; also referred to as the European Economic
Area). It is a visual identifier that the product meets the
requirements of one or more European directives. What is
a directive? To facilitate free trade and ensure the safety of
certain products, European countries, through the Euro-
pean Commission, have developed a series of standards, or
directives, as they are referred to, that manufacturers must
meet to legally export their products to European member
countries. These directives replace individual country stan-
dards because they relate principally to product safety.
Compliance with these directives is mandatory; it is a legal
obligation on the part of the manufacturer or the manufac-
turer’s agent. The Medical Devices Directive (MDD: 93/
42/EEC) is concerned with all medical devices. To obtain
the CE mark, a product must fulfill certain essential safety
and environmental requirements; however, the CE mark is
basically a measure that the European Union has adopted
to establish a single market and foster economic develop-
ment for member states, permitting products manufac-
tured (or imported) by a member state that do not present
a health, safety, or environmental threat to travel freely
among the other states.
Detailed information on CE marking can be found on
the official website of the European Union: http://europa.
eu.int/index_en.htm. In particular, the directive concern-
ing implantable medical devices can be found at the follow-
ing link (Annex 7 focuses on clinical evaluation of the
devices): http://europa.eu.int/eur-lex/en/consleg/pdf/
1990/en_1990L0385_do_001.pdf.
Insofar as the properties of the Endofit stent graft are
concerned, it is of note that the delivery system is as simple
as possible, being made up of a guide wire and a 24F
introducer sheath with its dilator, which is also used as a
pusher. However, once the graft is inserted into the intro-
ducer sheath, it cannot be advanced safely in the aorta
because the tip of the sheath is no longer tapered. There-
fore, if at this point of the procedure one realizes that the
Fig 7. Case 3. Left, Spiral computed tomography scan (sagittal view) shows incomplete opening of stent (arrow) in the
distal third of the endograft. Right, However, proximal end distal stents sealed the aneurysm satisfactorily.
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graft is too low in the aorta, the introducer sheath with the
graft must be withdrawn and the procedure started all over
again with a new introducer sheath, which may be cumber-
some and is time-consuming. The one intraoperative stroke
in this series might have been caused by atheromatous
dislodgment with the guide wire and introducer during
deployment of the stent graft.
During deployment, the upper stents of the device
open first; therefore a “parachute effect” is present, and
controlled systemic hypotension is advisable.1 Once the
proximal stent is open, corrections in positioning of the
stent graft are no longer safe, and the rest of the device
should be withdrawn from the sheath rapidly to avoid
involuntary displacement.
Initial deployment of the stent grafts in the desired
landing zone did not seem to be a problem; in fact, it was
successful in all patients. However, when the stent graft was
deployed in the distal aortic arch, a great deal of force was
needed, both to advance the device up to the desired
position and, in particular, to retract the introducer sheath
for deployment. Positioning and deployment in the de-
scending aorta was straightforward and much easier.
Regarding our learning curve, our previous experience
with endovascular exclusion of thoracic aortic disease com-
prised 29 patients who underwent treatment between June
1999 and October 2001 with the Excluder graft and 2
patients who received the Talent graft. Despite less experi-
ence with endovascular exclusion of aneurysms, the initial
results were definitely better. We recorded no 30-day mor-
tality (1 death at 3 months in a patient with chronic
dissection), no major morbidity, one type I endoleak in a
distal arch aneurysm (sealed spontaneously at 1 month), no
surgical conversion, and no graft migration. At mean fol-
low-up of 23 months, we have found no evidence of stent
rupture in the Excluder grafts.
Available devices are far from ideal, and several manu-
facturers are increasing their efforts to produce safer, but
also simpler and cheaper, devices. New devices have been
made commercially available in an attempt to overcome the
problems of existing devices; however, this is not always the
case.
In conclusion, endovascular treatment of thoracic dis-
eases with the Endofit graft in this small heterogeneous
group of patients demonstrated several problems that may
arise both from the delivery system and from the graft itself.
At present, we believe that other commercially available
endografts may be safer for endovascular treatment of
thoracic aortic disease.
We thank Michael John, Coordinator of English
courses at the Faculty of Medicine and Surgery, Vita-Salute
San Raffaele University, for help and suggestions regarding
linguistics.
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